[Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase].

Ting Yuan, Qian Jiang, Y Z Qin et al.|PubMed|2020

Cited by 3